Team identifies factors for COVID-19 vaccine protection
A comparison of immune correlates of AstraZeneca’s Phase II/III COVID-19 vaccine trial shows what antibodiy titer is required to prevent symptomatic disease.
EIF supports translational med with 25m
The EIF has invested 25m in the Prague-based i&i Biotech Fund I to boost biomedical tech transfer in Austria and Eastern Europe.
AstraZeneca puts 307m in Irish Alexion plant
Following the $39bn Alexion buy-out completed in July, AstraZeneca plc announced it will invest 307m in the company’s producion site near Dublin.
Touchlight extends funding round to boost DNA vector manufacture
UK-based DNA synthesis specialist Touchlight Ltd has extended a funding round to a current aggregate total of US $125m.
Swiss Biotech Day shows great biopharma ambitions
The Swiss biopharmaceutical industry is on the verge of record growth: This was demonstrated at the live Swiss Biotech Day in Basel.
EuropaBio lobbies for better Orphan Drug rules
EuropaBio has responded to the European Commissions public consultation on the Orphan Medicinal Products (OMPs) and Paediatrics Regulations.
Cardior bags 64m in Series B Financing
Cardior Pharmaceuticals GmbH is funding a Phase II trial with lead candidate CDR132L against mi-R132-induced heart failure.
ERS Genomics and Cellular Engineering Technologies collaborating
ERS Genomics and Cellular Engineering Technologies have entered into a CRISPR-Cas9 license agreement.
Visus Therapeutics cashes in 20m from LSP
Visus Therapeutics has baged a 20m stock financing to advance development of Brimochol for presbyopia